On October 8, 2026, Sequoia China announced the completion of a controlling acquisition of Jiangyin PeierTech Co., Ltd. (PeierTech) and its wholly-owned subsidiaries. Upon closing, Sequoia China holds approximately 80% equity in PeierTech, while the incumbent management team retains roughly 20% and will continue to oversee daily operations. Financial terms of the transaction were not disclosed.

Founded in 2002 and headquartered in Jiangyin, Jiangsu Province, PeierTech is one of China’s early specialists in the R&D and precision manufacturing of medical-grade Nitinol alloy. The company serves medical device manufacturers globally with a full-spectrum offering, spanning Nitinol wire and tubing, precision processes including laser cutting and heat setting, through to cleanroom assembly. Per corporate disclosures, its customer base covers more than 20 countries, with applications across cardiovascular, neurovascular, peripheral vascular, gastroenterology, orthopedics and other therapeutic fields.

This marks Sequoia China’s first controlling buyout targeting upstream materials and precision manufacturing within the medical device sector. Prior transactions of this type include takeovers of consumer platforms Marshall Group and Golden Goose Group, as well as the acquisition of Bayer’s global moxifloxacin antibiotic business. The addition of PeierTech extends Sequoia China’s M&A footprint deeper into the hardware-focused engineering and manufacturing layers of the medical device supply chain.

Nitinol: A Critical Material for Cardiovascular Interventional Devices

Clinicians and industry stakeholders in cardiology are familiar with Nitinol, a nickel‑titanium alloy distinguished by two unique mechanical properties: superelasticity and shape memory effect. Superelasticity enables the material to fully recover its original geometry after substantial deformation, while the shape memory effect triggers the alloy to revert to a predefined form at a target temperature. These attributes make Nitinol an irreplaceable structural material for self‑expanding vascular stents, transcatheter valve frames, interventional guidewires, filters and occluders, among other implantable and interventional devices.

For self‑expanding stents, the physician delivers the crimped implant to the lesion site via catheter before release; the stent expands autonomously via Nitinol’s superelasticity to appose the vessel wall, eliminating the need for balloon dilation. In transcatheter aortic valve replacement (TAVR), certain valve frames are also fabricated from Nitinol, leveraging shape memory for in‑vivo deployment and anchoring. Nitinol core wires inside interventional guidewires deliver optimal trackability and torque response to facilitate navigation through complex vascular anatomy.

Not all cardiovascular implants rely on Nitinol, however. Cobalt‑chromium and platinum‑chromium alloys remain dominant for coronary drug‑eluting stents, and some transcatheter valves adopt cobalt‑chromium frames. Material selection is driven by specific device design intent and clinical performance requirements. Nitinol occupies an important but niche technical role within cardiovascular device engineering.

From Wire Stock to Finished Components: PeierTech’s Business Model

To appreciate PeierTech’s value, it is important to distinguish between a material supplier and a contract manufacturer in medical device production.

Most medical device firms own product design and regulatory registration capabilities, yet rarely operate vertically integrated metallurgy lines. Nitinol preparation and processing carry high technical barriers: minor compositional drift alters transformation temperature, while drawing and heat treatment directly govern fatigue life. Implant‑grade Nitinol demands stringent consistency in chemical composition, inclusion control and surface quality. For device developers, partnering with an established Nitinol specialist is far more practical than building in‑house material production capacity.

PeierTech’s service portfolio is built around this market need. According to materials shared at Medtec China 2026, the company supplies Nitinol wire ranging from 0.013 mm to 6.0 mm in diameter, and tubing with outer diameters from 0.2 mm to 10.0 mm. Custom surface finishes including oxidized, clean, and bright pickled states, plus custom cross‑section profiles are available. Its wire and tubing are manufactured to ASTM F2063 and ASTM F2633 standards respectively. Speciality products such as platinum‑core radiopaque wire, GDP Nitinol wire and actuator wire are also offered.

Beyond raw materials, PeierTech extends downstream into precision fabrication and device assembly. Its laser cutting capability works with Nitinol tubing alongside stainless steel, cobalt‑chromium and titanium alloys to produce metallic stents and intricate components. Laser welding joins similar and dissimilar metals. Heat treatment and shape setting represent core workflows for Nitinol device production; the final geometry and mechanical performance of stents, occluders and other implants are heavily defined by setting protocols. Additional in‑house capabilities include braiding, surface modification (blasting, etching, electropolishing, passivation, plating) and guidewire fabrication.

On the assembly side, PeierTech operates ISO Class 7 (Class 10,000) and ISO Class 8 (Class 100,000) cleanrooms to carry out stamping, heat shrinking, welding, bonding, suturing and coating operations. Its volume‑produced component catalogue includes stone retrieval baskets, occlusion baskets, a broad range of medical guidewires, snares and covered stents. It should be noted that most of these outputs are manufactured on a contract basis for downstream OEM partners; PeierTech generally does not hold marketing approvals to sell these finished devices directly to end markets.

Since 2004, PeierTech has maintained ISO 13485 certification issued by BSI. This foundational medical device quality system certification does not equate to individual product clearances under FDA, CE or NMPA frameworks, yet it is a prerequisite qualification to serve international device OEMs.

This integrated “material‑to‑component‑to‑assembly” value chain is uncommon among domestic Nitinol fabricators. For downstream customers, consolidating work with a single vendor shortens development timelines, reduces interface risk and enables tighter quality control. This underpins PeierTech’s core “one‑stop” value proposition.

Why Sequoia China Pursued a Controlling Stake

An 80% controlling acquisition differs fundamentally from minority equity investment. Minority investors deploy capital for financial returns and typically refrain from direct operational oversight. Control ownership grants the investor effective decision‑making authority, with deep involvement in governance, resource allocation and corporate strategy.

From Sequoia China’s perspective, PeierTech exhibits several traits well‑suited to a control buyout. First, it is a mature manufacturing enterprise with more than two decades of operating history, beyond the technology validation or business model exploration phase. Second, it serves both domestic and international markets with customers spread across 20+ countries, laying a foundation for global expansion. Third, Nitinol precision manufacturing features long customer qualification cycles and high switching costs; once validated into the supply chain of leading device OEMs, commercial relationships tend to be stable and recurring.

Jia Qin, Partner at Sequoia China, stated in the transaction announcement that the investment is rooted in long‑term enablement. The firm aims to preserve operational continuity while fostering strategic collaboration between PeierTech and its clients and partners. The retention of the founding management team with a 20% equity stake, paired with a new management equity incentive plan from Sequoia China, is structured to stabilise core talent and safeguard ongoing customer relationships. Shen Bin, CEO of PeierTech, commented that the deal brings not only capital but also global perspective and industrial ecosystem resources.

Widening the lens, Sequoia China closed a RMB 18 billion fundraising round in July 2024. For large‑balance‑sheet institutional investors, controlling M&A accommodates larger individual cheque sizes and allows value creation through operational improvements and portfolio synergy. Amid intensified competition in the primary market and constrained exit avenues, control buyouts have become a key allocation strategy for leading investment firms.

What This Means for the Cardiovascular Device Industry

PeierTech’s end markets span multiple clinical specialties, yet from a cardiovascular viewpoint, Nitinol materials and precision fabrication form foundational infrastructure for the sector. Self‑expanding stents, covered stents, flow diverters, occluders and interventional guidewires used daily in clinical practice all rely on upstream suppliers delivering consistent, batch‑stable Nitinol feedstock and precision machining.

For years, the global medical Nitinol market has been dominated by a small group of overseas suppliers. PeierTech ranks among China’s longest‑established domestic players in this space, with its products and services already integrated into device supply chains across multiple nations. Capital and global resource backing from Sequoia China may accelerate penetration among top international OEMs. For Chinese cardiovascular device developers, domestic substitution of critical upstream materials remains central to supply chain resilience. A better‑resourced domestic Nitinol supplier may deliver more stable, cost‑competitive material options for local device manufacturers.

That said, the transaction has only just closed, and outcomes remain to be proven. Public disclosures do not include PeierTech’s revenue, profitability, capacity utilisation or granular customer breakdowns, nor can we confirm which specific cardiovascular devices incorporate PeierTech‑sourced materials or components. The controlling acquisition marks only the starting line. Whether capital translates into expanded customer reach, upgraded technical capacity and sustainable operational growth will be tested over the coming years through tangible operating performance. October 9, 2026